When multiple myeloma returns after initial treatment, accessing specialized expertise through a second opinion can reveal treatment options unavailable at community cancer centers, including CAR-T cell therapy, bispecific antibodies, and clinical trial opportunities. Key Takeaways Second opinions from high-volume myeloma specialists provide access to 2026 treatment advances including CAR-T therapy and bispecific antibodies not available at all centers Virtual teleconsultatio